Novartis AG (NVS) Stock Analysis & Winston Score

Novartis is a Swiss pharmaceutical company that discovers, makes, and sells prescription medicines to patients around the world. Its key drugs treat conditions like heart failure, cancer, multiple sclerosis, and eye diseases — with major products including Entresto, Kisqali, Kesimpta, and Cosentyx. It is one of the largest pharmaceutical companies in the world by revenue. Novartis earns money primarily by selling branded prescription drugs to hospitals, pharmacies, and healthcare systems, which are then reimbursed through insurance or government health programs. The company operates globally, with strong sales across the United States, Europe, and emerging markets, generating roughly $45 billion in annual revenue. Its main competitive advantages are its deep drug pipeline and the patent protection on its medicines, but the biggest ongoing risk is patent expiration — when key drugs lose exclusivity, cheaper generic versions enter the market and can sharply reduce revenue.